Groups like CSRxP and Patents for Affordable Drugs NOW have recently ramped up their rhetoric on pharmaceutical patents. Having long criticized so-called “patent thickets,” they are now warning about “serial patents,” which they claim are nothing more than a deliberate tactic to delay generic competition. It’s a loud and attention-grabbing talking point — but it’s not an accurate reflection of how the patent system works.
At the heart of this debate is a basic question: what actually makes a patent valid?
For an invention to qualify for a patent under U.S. law, it must be new, novel, and non-obvious. That is not a rubber stamp. Patent examiners review applications against prior art and established scientific literature to ensure the claimed invention represents a genuine advance. A company cannot simply re-file the same invention repeatedly or obtain a new patent for the identical product to extend exclusivity. If it’s the same invention, it won’t meet the legal standard.
This is where the “serial patents” narrative breaks down. The implication is that companies are stacking identical or trivial patents to game the system. But patents are not awarded for repetition. They are granted for distinct inventions — new formulations, new delivery mechanisms, new methods of treatment, or newly discovered clinical benefits — each of which must independently satisfy strict statutory criteria.
Drug development does not freeze at the moment of FDA approval. In many cases, approval marks the beginning of further research to improve a therapy’s safety profile, dosing schedule, stability, or usefulness for additional patient populations. Those improvements require investment, clinical testing, and regulatory review. When they result in something truly new and non-obvious, they may qualify for patent protection. That is not abuse; it is the system functioning as designed.
Consider how certain medicines evolve. Botox, for instance, was initially approved for two rare eye disorders. Post-approval R&D led to approvals for chronic migraine, muscle spasticity, and several other conditions. Each new therapeutic use required evidence and innovation. The associated patents protect those specific advances — not the original approval indefinitely.
Before accepting sweeping narratives about patent abuse, it’s worth remembering how the system is structured. Patents are not granted for hype or duplication. They are granted for new and non-obvious advances. Weakening that framework based on a misleading slogan — no matter how inflammatory — would make it harder to sustain the incremental innovations that improve treatments and expand options for patients.